ELK1 inhibition alleviates amyloid pathology and memory decline by promoting the SYVN1-mediated ubiquitination and degradation of PS1 in Alzheimer’s disease. Here, SYVN1 is linked to early-onset autosomal dominant Alzheimer disease.